AstraZeneca (LON:AZN) Earns Buy Rating from Shore Capital
Shore Capital reiterated their buy rating on shares of AstraZeneca (LON:AZN) in a report issued on Wednesday morning, Digital Look reports.
Other equities analysts also recently issued research reports about the stock. Credit Suisse Group set a GBX 7,300 ($95.39) price target on shares of AstraZeneca and gave the company a buy rating in a report on Friday, July 26th. Liberum Capital reiterated a hold rating and issued a GBX 6,400 ($83.63) price target on shares of AstraZeneca in a report on Wednesday, August 28th. Citigroup restated a buy rating and set a £100 ($130.67) target price (up from GBX 7,000 ($91.47)) on shares of AstraZeneca in a report on Wednesday, September 11th. Bank of America set a GBX 8,500 ($111.07) target price on shares of AstraZeneca and gave the company a buy rating in a report on Friday, September 13th. Finally, Bryan, Garnier & Co restated a neutral rating on shares of AstraZeneca in a report on Wednesday, July 3rd. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have issued a buy rating to the stock. The stock has a consensus rating of Hold and an average price target of GBX 7,050 ($92.12).
Shares of AZN opened at GBX 7,167 ($93.65) on Wednesday. The company has a 50-day simple moving average of GBX 7,191.39 and a 200-day simple moving average of GBX 6,415.44. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 144.48. The company has a market capitalization of $94.02 billion and a PE ratio of 41.86. AstraZeneca has a 52-week low of GBX 5,312 ($69.41) and a 52-week high of GBX 7,583 ($99.09).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: What causes a yield curve to invert?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.